Citadel Advisors
IMVT icon

Citadel Advisors’s Immunovant IMVT Stock Holding History

Citadel Advisors’s Portfolio IMVT Stock Details IMVT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.37M Sell
55,200
-3,600
-6% -$93.2K ﹤0.01% 6927
2025
Q4 		$1.49M Sell
58,800
-31,800
-35% -$709K ﹤0.01% 6519
2025
Q3 		$1.46M Buy
90,600
+23,400
+35% +$379K ﹤0.01% 6722
2025
Q2 		$1.08M Sell
67,200
-80,800
-55% -$1.22M ﹤0.01% 6930
2025
Q1 		$2.53M Sell
148,000
-4,500
-3% -$94.1K ﹤0.01% 5086
2024
Q4 		$3.78M Buy
152,500
+53,800
+55% +$1.53M ﹤0.01% 4435
2024
Q3 		$2.81M Buy
98,700
+39,500
+67% +$1.16M ﹤0.01% 4904
2024
Q2 		$1.56M Buy
59,200
+35,400
+149% +$1.01M ﹤0.01% 5766
2024
Q1 		$769K Sell
23,800
-1,100
-4% -$40.1K ﹤0.01% 7476
2023
Q4 		$1.05M Sell
24,900
-103,300
-81% -$3.8M ﹤0.01% 6579
2023
Q3 		$4.92M Buy
128,200
+116,000
+951% +$2.62M ﹤0.01% 3670
2023
Q2 		$231K Buy
12,200
+900
+8% +$16.8K ﹤0.01% 9566
2023
Q1 		$175K Buy
11,300
+10,000
+769% +$174K ﹤0.01% 10396
2022
Q4 		$23.1K Buy
+1,300
New +$16.4K ﹤0.01% 13029
2022
Q2 		– Sell
-11,100
Closed -$61K – 13451
2022
Q1 		$61K Sell
11,100
-43,200
-80% -$269K ﹤0.01% 12666
2021
Q4 		$463K Sell
54,300
-139,600
-72% -$1.15M ﹤0.01% 9887
2021
Q3 		$1.69M Buy
193,900
+7,900
+4% +$71.3K ﹤0.01% 6802
2021
Q2 		$1.97M Buy
186,000
+160,600
+632% +$2.24M ﹤0.01% 6665
2021
Q1 		$407K Buy
+25,400
New +$670K ﹤0.01% 10138

Other funds holding IMVT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Citadel Advisors's IMVT Position: Q1 2026 in Review

Citadel Advisors reduced its Immunovant (IMVT) stake by 6.5% in Q1 2026, selling an estimated $262K and leaving 144,398 shares worth $3.59M. The position accounts for ﹤0.01% of the portfolio, ranked #4918.

Citadel Advisors first reported a position in IMVT in Q1 2020 and has held it in 25 quarters since. The position peaked at $35.5M in Q4 2020. 215 funds tracked by Wall St. Rank hold IMVT as of Q1 2026.

  • Citadel Advisors held 144,398 shares of Immunovant worth $3.59M as of Q1 2026.
  • Citadel Advisors sold 10,109 Immunovant shares in Q1 2026, an estimated $262K.
  • Immunovant made up ﹤0.01% of Citadel Advisors's portfolio in Q1 2026, its #4918 holding.
  • Citadel Advisors first reported a position in Immunovant in Q1 2020 and has held it in 25 quarters since.
  • Citadel Advisors's Immunovant position peaked at $35.5M in Q4 2020.
  • 215 funds tracked by Wall St. Rank held Immunovant as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.